Announcements Trials
Browse Landscape

Phase

Phase 2 61Phase 1 39Phase 1/2 17Phase 3 14Phase NA 12Phase EARLY_PHASE1 5Phase 4 1Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3Head & Neck 3Thoracic 2Other hematologic neoplasm 2Genitourinary 2Sarcoma 1Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Adenocarcinoma Of Esophagus 1

Interventions

Oxaliplatin 49Fluorouracil 46Capecitabine 41Cisplatin 36Gemcitabine 29Leucovorin 27Bevacizumab 21Drug Therapy 20Paclitaxel 15Folfox protocol 15Radiotherapy 14Irinotecan 14apatinib 11Neoadjuvant Therapy 11Docetaxel 11sintilimab 9S 1 (combination) 9Sorafenib 8Nivolumab 8Trastuzumab 7Surgical Procedures, Operative 7Magnetic Resonance Spectroscopy 7lenvatinib 6atezolizumab 6XELOX 6Cetuximab 6Albumin-Bound Paclitaxel 6130-nm albumin-bound paclitaxel 6tislelizumab 5pembrolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Specimen Handling × Gastrointestinal × Clear all
NCT06203600 2026-05-26

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
224 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡